Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study

Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test‐negative study.

[1]  H. Whitaker,et al.  Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023 , 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  G. Neumann,et al.  Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023 , 2023, MMWR. Morbidity and mortality weekly report.

[3]  D. Skowronski,et al.  Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23 , 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  M. Valenciano,et al.  Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study , 2022, Influenza and other respiratory viruses.

[5]  Aman Verma,et al.  Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors , 2021, medRxiv.

[6]  M. Valenciano,et al.  Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  M. Valenciano,et al.  Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18) , 2019, Vaccine: X.

[8]  M. Valenciano,et al.  2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children , 2018, Influenza and other respiratory viruses.

[9]  U. Buchholz,et al.  I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  U. Buchholz,et al.  Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  M. Valenciano,et al.  I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe , 2011, PloS one.

[12]  M. Valenciano,et al.  Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study , 2011, PLoS medicine.

[13]  M. Valenciano,et al.  "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[15]  Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. , 2012, Releve epidemiologique hebdomadaire.